BeiGene, Ltd.: management transactions · United States · SEC (Form 4)

About BeiGene, Ltd.

BeiGene, Ltd. (ticker BGNE) is an oncology-focused biopharmaceutical company listed on the U.S. NASDAQ exchange in the United States. Although the company completed a legal name change in 2025 to BeOne Medicines Ltd., BGNE remains the long-standing market identifier associated with the business in many market databases and investor references. For international equity investors, the key investment case is a global cancer franchise that has evolved from a research-driven biotech into a more mature, commercial-stage oncology platform with meaningful geographic reach. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1651308/000110465925052750/tm2515777d13_8k.htm?utm_source=openai)) Founded in 2010, the company has built an integrated model spanning discovery research, clinical development, manufacturing, and commercialization. Its strategy is explicitly oncology-first, with a broad footprint across the United States, Europe, and Asia. The company states that it does not have a single corporate headquarters in the traditional sense, but its major operating locations include San Carlos, California; Cambridge, Massachusetts; Hopewell, New Jersey; and a research center in Beijing, underscoring a distributed global operating structure. ([beigene.com](https://www.beigene.com/wp-content/uploads/2024/04/BeiGene-2023-RBS-Report_4-24-24.pdf?utm_source=openai)) The core asset base centers on three marketed medicines: BRUKINSA (zanubrutinib), a BTK inhibitor used in several blood cancers; TEVIMBRA (tislelizumab-jsgr), an anti-PD-1 monoclonal antibody; and PAMIPARIB, a PARP1/PARP2 inhibitor. In commercial terms, BRUKINSA and TEVIMBRA are the principal growth engines, while the pipeline remains extensive. The company highlights more than 175 clinical trials worldwide, over 30,000 patients enrolled globally, and more than 40 clinical and commercial-stage assets under exploration, which reflects a pipeline depth that is notable for a company of this size. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1651308/000165130824000014/bgne-20231231.htm?utm_source=openai)) Competitively, BeiGene sits in a crowded global oncology landscape against major multinational pharma companies and specialist cancer biotechs. Its differentiator is the combination of internal discovery, late-stage clinical execution, and a broad commercialization engine that can support launches across multiple regions. The company also reported gaining approvals in 14 new countries in 2024, indicating continued geographic expansion and regulatory execution. ([beigene.com](https://www.beigene.com/responsibility/advancing-global-health/?utm_source=openai)) Recent corporate milestones are important for context. On May 27, 2025, the company completed a continuation transaction moving its jurisdiction of incorporation from the Cayman Islands to Switzerland and changed its English name to BeOne Medicines Ltd. On the operating side, management reported strong 2025 revenue growth in its third-quarter update, with BRUKINSA remaining a major driver. For investors, the story is a globally scaled oncology platform where commercial execution, label expansion, and pipeline delivery are the main value drivers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1651308/000110465925052750/tm2515777d13_8k.htm?utm_source=openai))